Table 1 Characteristics of patients with metastatic breast cancer treated with trastuzumab
From: Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
Number in study group | 93 |
Median age (range) | 48 (23–76) |
HER2 immunohistochemistry | |
 2+ | 6 |
 3+ | 87 |
Hormone receptor status | |
 ER+ | 41 (44%) |
 ER | 52 (56%) |
 ER | 47 (51%) |
 ER | 5 (5%) |
Trastuzumab given | |
 Alone | 30 (32%) |
 With chemotherapy | 53 (57%) |
 With hormonal therapy | 8 (9%) |
 With chemotherapy and hormonal therapy | 2 (2%) |
Line of therapy for trastuzumab | |
 First systemic therapy | 44 (47%) |
 Second systemic therapy | 31 (33%) |
 Third line systemic therapy | 18 (19%) |
Disease distribution at the start of trastuzumab therapy | |
 Visceral | 51 (55%) |
 Nonvisceral | 42 (45%) |
Response to trastuzumab | |
 Stable disease or better | 53 (57%) |
 PD | 33 (35%) |
 Not assessed/not assessable | 7 (8%) |
